Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
October 24, 2021 15:30 ET | Phathom Pharmaceuticals
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical ResearchPhase 1 population PK data abstract concludes the...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
October 18, 2021 07:00 ET | Phathom Pharmaceuticals
Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phasesVonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus...
PAVMEDLOGONEW15OCT2018.png
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
October 07, 2021 11:41 ET | PAVmed Inc.
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
September 20, 2021 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
August 31, 2021 07:45 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
August 10, 2021 08:00 ET | Phathom Pharmaceuticals
Pivotal Phase 3 PHALCON-EE trial topline data for vonoprazan in erosive esophagitis expected in October 2021Phase 2 PHALCON-NERD on-demand trial for vonoprazan in non-erosive reflux disease enrolling...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
August 02, 2021 08:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
gmi logo.jpg
Endoluminal Suturing Devices Market revenue to cross USD 119.8 Mn by 2027: Global Market Insights Inc.
July 22, 2021 07:00 ET | Global Market Insights, Inc
Selbyville, Delaware, July 22, 2021 (GLOBE NEWSWIRE) -- According to latest report “Endoluminal Suturing Devices Market by Application (Bariatric Surgery Gastrointestinal Defects, Gastroesophageal...
PAVMEDLOGONEW15OCT2018.png
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
March 02, 2020 09:30 ET | PAVmed Inc.
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and...
PAVMEDLOGONEW15OCT2018.png
PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test
December 19, 2019 09:30 ET | PAVmed Inc.
First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer First patients to undergo testing...